Pediatric Neurology
Volume 25, Issue 3 , Pages 199-207 , September 2001

Antiepileptic drugs: affective use in autism spectrum disorders

  • Adriana Di Martino, MD

      Affiliations

    • Department of Neuroscience; Child Neurology and Psychiatry; University of Cagliari; Cagliari, Italy
    • ,
  • Roberto F Tuchman, MD

      Affiliations

    • Department of Neurology; Dan Marino Center; Miami Children’s Hospital; Weston, Florida, USA
    • Corresponding Author InformationCommunications should be addressed to: Dr. Tuchman; Director; Dan Marino Center; Department of Neurology; Miami Children’s Hospital; 2900 South Commerce Parkway; Weston, FL 33331

Received 10 November 2000 ,Accepted 5 March 2001.

References 

  1. Tuchman RF, Rapin I, Shinnar S. Autistic and dysphasic children. I (Clinical characteristics). Pediatrics. 1991;88:1211–1218
  2. Deykin E, MacMahon B. The incidence of seizures among children with autistic symptoms. Am J Psychiatry. 1979;136:1310–1312
  3. Olsson I, Steffenburg S, Gillberg C. Epilepsy in autism and autistic-like conditions. A population-based study. Arch Neurol. 1988;45:666–668
  4. Tuchman RF, Rapin I, Shinnar S. Autistic and dysphasic children. II (Epilepsy). [published erratum appears in Pediatrics 1992;90(Pt 1):264] Pediatrics. 1991;88:1219–1225
  5. Volkmar FR, Cohen DJ. Comorbid association of autism and schizophrenia. Am J Psychiatry. 1991;148:1705–1707
  6. Tuchman R, Rapin I. Regression in pervasive developmental disorders (Seizures and epileptiform electroencephalogram correlates). Pediatrics. 1997;99:560–566
  7. Aarts J, Binnie C, Smit A, Wilkins A. Selective cognitive impairment during focal and generalized epileptiform EEG activity. Brain. 1984;107:293–308
  8. Shewmon DA, Erwin RJ. The effect of focal interictal spikes on perception and reaction time. II. Neuroanatomic specificity. Electroencephalogr Clin Neurophysiol. 1988;69:338–352
  9. Shewmon DA, Erwin RJ. The effect of focal interictal spikes on perception and reaction time. I. General considerations. Electroencephalogr Clin Neurophysiol. 1988;69:319–337
  10. Lainhart JE, Folstein SE. Affective disorders in people with autism (A review of published cases). J Autism Dev Disord. 1994;24:587–601
  11. Aman MG, Van Bourgondien ME, Wolford PL, Sarphare G. Psychotropic and anticonvulsant drugs in subjects with autism (Prevalence and patterns of use). J Am Acad Child Adolesc Psychiatry. 1995;34:1672–1681
  12. Gillberg C, Schaumann H. Epilepsy presenting as infantile autism? Two case studies. Neuropediatrics. 1983;14:206–212
  13. Komoto J, Usui S, Hirata J. Infantile autism and affective disorder. J Autism Dev Disord. 1984;14:81–84
  14. Sovner R. The use of valproate in the treatment of mentally retarded persons with typical and atypical bipolar disorders. J Clin Psychiatry. 1989;50(Suppl):40–43
  15. Nass R, Petrucha D. Acquired aphasia with convulsive disorder (A pervasive developmental disorder variant). J Child Neurol. 1990;5:327–328
  16. Deonna T, Ziegler AL, Moura-Serra J, Innocenti G. Autistic regression in relation to limbic pathology and epilepsy (Report of two cases). Dev Med Child Neurol. 1993;35:166–176
  17. Uvebrant P, Bauziene R. Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics. 1994;25:284–289
  18. Plioplys AV. Autism (Electroencephalogram abnormalities and clinical improvement with valproic acid). Arch Pediatr Adolesc Med. 1994;148:220–222
  19. Rittey CD. Case summary (Benjamin). Seizure. 1994;3(Suppl A):25–27
  20. Childs JA, Blair JL. Valproic acid treatment of epilepsy in autistic twins. J Neurosci Nurs. 1997;29:244–248
  21. Damore J, Stine J, Brody L. Medication-induced hypomania in Asperger’s disorder. [letter] J Am Acad Child Adolesc Psychiatry. 1998;37:248–249
  22. Rutter M, Graham P, Yule W. A neuropsychiatric study in childhood. Clinics in Developmental Medicine No.35/36. London: Spastics International Medical Publications, 1970.
  23. Pond DA. Psychiatric disorders accompanying epilepsy in children. Rev Neuropsychiatr Infant. 1970;18:505–510
  24. Pond DA. The psychological disorders of epileptic patients. Psychiatr Neurol Neurochir. 1971;74:159–162
  25. Cadman D, Boyle M, Szatmari P, Offord DR. Chronic illness, disability, and mental and social well-being (Findings of the Ontario Child Health Study). Pediatrics. 1987;79:805–813
  26. Hoare P. Psychiatric disturbance in the familiesof epileptic children. Dev Med Child Neurol. 1984;26:14–19
  27. Gillberg C. Psychiatric and behavioral problem in epilepsy, hydrocephalus and cerebral pulsy. In:  Aicardi J editors. Diseases of the nervous system in childhood. 2nd ed.. Oxford: Cambridge University Press; 1998;p. 865–867
  28. Kim WJ. Psychiatric aspects of epileptic children and adolescents. J Am Acad Child Adolesc Psychiatry. 1991;30:874–886
  29. Betts T. Depression, anxiety, and epilepsy. In:  Reynolds E,  Trimble M editor. Epilepsy and psychiatry. London: Churchill Livingstone; 1981;p. 60–71
  30. Kogeorgos J, Fonagy P, Scott DF. Psychiatric symptom patterns of chronic epileptics attending a neurological clinic (A controlled investigation). Br J Psychiatry. 1982;140:236–243
  31. Perini GI, Tosin C, Carraro C, et al.  Interictal mood and personality disorders in temporal lobe epilepsy and juvenile myoclonic epilepsy. J Neurol Neurosurg Psychiatry. 1996;61:601–605
  32. Victoroff JI, Benson F, Grafton ST, Engel J, Mazziotta JC. Depression in complex partialseizures. Electroencephalography and cerebral metabolic correlates. Arch Neurol. 1994;51:155–163
  33. Brent DA. Overrepresentation of epileptics in a consecutive series of suicide attempters seen at a children’s hospital, 1978-1983. J Am Acad Child Psychiatry. 1986;25:242–246
  34. Bowring MA, Kovacs M. Difficulties in diagnosing manic disorders among children and adolescents. J Am Acad Child Adolesc Psychiatry. 1992;31:611–614
  35. Wozniak J, Biederman J, Kiely K, et al.  Mania-like symptoms suggestive of childhood-onset bipolar disorder in clinically referred children. [see comments] J Am Acad Child Adolesc Psychiatry. 1995;34:867–876
  36. American Psychlogical Association . Practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. [see comments] J Am Acad Child Adolesc Psychiatry. 1998;37(Suppl 10):27S–45S
  37. Blumer D. Antidepressant and double antidepressant treatment for the affective disorder of epilepsy. J Clin Psychiatry. 1997;58:3–11
  38. Rutter M, Greenfeld D, Lockyer L. A five to fifteen year follow-up study of infantile psychosis. II. Social and behavioural outcome. Br J Psychiatry. 1967;113:1183–1199
  39. Simons JM. Observations on compulsive behavior in autism. J Autism Child Schizoph. 1974;4:1–10
  40. Ghazzidium MLT. Depression in autistic disorder. Br J Psychiatry. 1991;159:721–723
  41. Gillberg C. Asperger’s syndrome and recurrent psychosis—A case study. J Autism Dev Disord. 1985;21:61–77
  42. Steingard R, Biederman J. Lithium responsive manic-like symptoms in two individuals with autism and mental retardation. J Am Acad Child Adol Psychiatry. 1987;26:932–935
  43. Kerbeshian J, Burd L. Case study (Comorbidity among Tourette’s syndrome, autistic disorder, and bipolar disorder). J Am Acad Child Adolesc Psychiatry. 1996;35:681–685
  44. Comings D, Comings B. Clinical and genetic relationship between autism-pervasive developmental disorder and Tourette syndrome (A sudy of 19 cases). Am J Med Genet. 1991;39:180–191
  45. Sverd J, Montero G, Gurevich N. Brief report (Cases for an association between Tourette syndrome, autistic disorder, and schizophrenia-like disorder). J Autism Dev Disord. 1993;23:407–413
  46. Baron-Cohen S, Mortimore C, Moriarty J, Izaguirre J, Robertson M. The prevalence of Gilles de la Tourette’s syndrome in children and adolescents with autism. J Child Psychol Psychiatry. 1999;40:213–218
  47. Granana N, Tuchman RF. A child with severe head banging. Semin Pediatr Neurol. 1999;6:221–224
  48. Post RM. Introduction (Emerging perspectives on valproate in affcetive disorders). J Clin Psychopharmacol. 1989;50(Suppl.):3–9
  49. Wauquier A, Zhou S. Topiramate (A potent anticonvulsant in the amygdala-kindled rat). Epilepsy Res. 1996;24:73–77
  50. Otsuki K, Morimoto K, Sato K, Yamada N, Kuroda S. Effects of lamotrigine and conventional antiepileptic drugs on amygdala- and hippocampal-kindled seizures in rats. Epilepsy Res. 1998;31:101–112
  51. Loscher W. Neurophysiologic and neurochemical principles of the effect of anticonvulsants. Fortschr Neurol Psychiatr. 1987;55:145–157
  52. Goddard GV, Douglas RM. Does the engram of kindling model the engram of normal long term memory?. Can J Neurol Sci. 1975;2:385–394
  53. Post RM, Altshuler LL, Ketter TA, Denicoff K, Weiss SR. Antiepileptic drugs in affective illness. Clinical and theoretical implications. Adv Neurol. 1991;55:239–277
  54. Post RM, Putnam F, Uhde TW, Weiss SR. Electroconvulsive therapy as an anticonvulsant. Implications for its mechanism of action in affective illness. Ann NY Acad Sci. 1986;462:376–388
  55. Weiss SR, Post RM. Kindling (Separate vs. shared mechanisms in affective disorders and epilepsy). Neuropsychobiology. 1998;38:167–180
  56. Post RM, Weiss SR. Sensitization and kindling phenomena in mood, anxiety, and obsessive-compulsive disorders (The role of serotonergic mechanisms in illness progression). Biol Psychiatry. 1998;44:193–206
  57. Wada Y, Shiraishi J, Nakamura M, Koshino Y. Role of serotonin receptor subtypes in the development of amygdaloid kindling in rats. Brain Res. 1997;747:338–342
  58. During MJ, Craig JS, Hernandez TD, Anderson GM, Gallager DW. Effect of amygdala kindling on the in vivo release of GABA and 5-HT in the dorsal raphe nucleus in freely moving rats. Brain Res. 1992;584:36–44
  59. Marcoli M, Maura G, Tortarolo M, Raiteri M. Serotonin inhibition of the NMDA receptor/nitric oxide/cyclic GMP pathway in rat cerebellum (Involvement of 5-hydroxytryptamine2C receptors). J Neurochem. 1997;69:427–430
  60. Farber NB, Newcomer JW, Olney JW. The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer’s disease. Prog Brain Res. 1998;116:421–437
  61. Okada M, Hirano T, Mizuno K, et al.  Effects of carbamazepine on hippocampal serotonergic system. Epilepsy Res. 1998;31:187–198
  62. Yan QS, Mishra PK, Burger RL, Bettendorf AF, Jobe PC, Dailey JW. Evidence that carbamazepine and antiepilepsirine may produce a component of their anticonvulsant effects by activating serotonergic neurons in genetically epilepsy-prone rats. J Pharmacol Exp Ther. 1992;261:652–659
  63. Dailey JW, Reith ME, Steidley KR, Milbrandt JC, Jobe PC. Carbamazepine-induced release of serotonin from rat hippocampus in vitro. Epilepsia. 1998;39:1054–1063
  64. Shukla VK, Garg SK, Mathur VS, Kulkarni SK. GABAergic, dopaminergic and cholinergic interactions in perphenazine-induced catatonia in rats. Arch Int Pharmacodyn Ther. 1985;278:236–248
  65. Whitton P, Oreskovic D, Jernej B, Bulat M. Effect of valproic acid on 5-hydroxytriptamine turnover in muose brain. J Pharm Pharmacol. 1985;37:199–200
  66. Horton RW, Anlezark GM, Sawaya MC, Meldrum BS. Monoamine and GABA metabolism and the anticonvulsant action of di-n-propylacetate and ethanolamine-O-sulphate. Eur J Pharmacol. 1977;41:387–397
  67. Hwang EC, Van Woert MH. Effect of valproic and acid on serotonin metabolism. Neuropharmacology. 1979;18:391–397
  68. Baf MH, Subhash MN, Lakshmana KM, Rao BS. Sodium valproate induced alterations in monoamine levels in different regions of the rat brain. Neurochem Int. 1994;24:67–72
  69. Southam E, Kirkby D, Higgins GA, Hagan RM. Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats. Eur J Pharmacol. 1998;358:19–24
  70. von Wegerer J, Hesslinger B, Berger M, Walden J. A calcium antagonistic effect of the new antiepileptic drug lamotrigine. Eur Neuropsychopharmacol. 1997;7:77–81
  71. Rao ML, Clarenbach P, Vahlensieck M, Kratzschmar S. Gabapentin augments whole blood serotonin in healthy young men. J Neural Transm. 1988;73:129–134
  72. Ben-Menachem E, Persson LI, Hedner T. Selected CSF biochemistry and gabapentin concentrations in the CSF and plasma in patients with partial seizures after a single oral dose of gabapentin. Epilepsy Res. 1992;11:45–49
  73. Suzdak PD, Gianutsos G. Differential coupling of GABA-A and GABA-B receptors to the noradrenergic system. J Neural Transm. 1985;62:77–89
  74. Yessaian NH, Armenian AR, Buniatian HC. Effect of gamma-aminobutyric acid on brain serotonin and catecholamines. J Neurochem. 1969;16:1425–1433
  75. Prosser J, Hughes CW, Sheikha S, et al.  Plasma GABA in children and adolescents with mood, behavior, and comorbid mood and behavior disorders (A preliminary study). J Child Adolesc Psychopharmacol. 1997;7:181–199
  76. Petty F, Kramer GL, Fulton M, Moeller FG, Rush AJ. Low plasma GABA is a trait-like marker for bipolar illness. Neuropsychopharmacology. 1993;9:125–132
  77. Petty F. Plasma concentrations of gamma-aminobutyric acid (GABA) and mood disorders (A blood test for manic depressive disease?). Clin Chem. 1994;40:296–302
  78. Petty F, Kramer GL, Fulton M, Davis L, Rush AJ. Stability of plasma GABA at four-year follow-up in patients with primary unipolar depression. Biol Psychiatry. 1995;37:806–810
  79. Petty F, Rush AJ, Davis JM, et al.  Plasma GABA predicts acute response to divalproex in mania. Biol Psychiatry. 1996;39:278–284
  80. Meldrum BS. Update on the mechanism of action of antiepileptic drugs. Epilepsia. 1996;37(Suppl 6):S4–S11
  81. Concas A, Mascia MP, Sanna E, Santoro G, Serra M, Biggio G. ‘In vivo’ administration of valproate decreases t-[35S]butylbicyclophosphorothionate binding in the rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1991;343:296–300
  82. Loscher W, Siemes H. Valproic acid increases gamma-aminobutyric acid in CSF of epileptic children. Lancet. 1984;2:225
  83. Loscher W, Vetter M, Bohme G, Stoltenburg-Didinger G. In vivo effects of anticonvulsant drugs on nerve terminal (synaptosomal) GABA levels in 11 brain regions of the rat. J Neural Transm. 1985;63:157–167
  84. Loscher W. Correaltion between alterations in brain GABA metabolism and seizure excitability folllowing administration of GABA aminitransferase inhibitors and valproic acid—a reevaluation. Neurochem Int. 1981;3:397–404
  85. Godin Y, Heiner L, Mark J, Mandel P. Effects of DI-n-propylacetate, and anticonvulsive compound, on GABA metabolism. J Neurochem. 1969;16:869–873
  86. Moshé SL. Mechanisms of action of anticonvulsant agents. Neurology. 2000;55:S32–S40[discussion 55:S54-38]
  87. White HS. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia. 1997;38(Suppl 1):S9–S17
  88. Petroff OA, Rothman DL, Behar KL, Lamoureux D, Mattson RH. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol. 1996;39:95–99
  89. Lampe H, Bigalke H. Carbamazepine blocks NMDA-activated currents in cultured spinal cord neurons. Neuroreport. 1990;1:26–28
  90. Myazaki C, Natsuyama K, Ichikawa M, Goto S. Effect of VPA on cerebral aminoacids (Mechanism of GABA elevation and possible casua relation of VPA induced encephalopaty and glutamine level). Chem Pharm Bull. 1988;36:3589–3594
  91. Messenheimer JA. Lamotrigine. Epilepsia. 1995;36(Suppl 2):S87–S94
  92. Xie X, Lancaster B, Peakman T, Garthwaite J. Interaction of antiepileptic drug lamotrigine with the recombinant rat brain type IIA Na+ channels and with native Na+ channels in rat hippocampal neurones. Pflugers Arch. 1995;430:437–446
  93. Goldlust A, Su TZ, Welty DF, Taylor CP, Oxender DL. Effects of anticonvulsant drug gabapentin on the enzymes in metabolic pathways of glutamate and GABA. Epilepsy Res. 1995;22:1–11
  94. Dailey JW, Reith ME, Yan QS, Li MY, Jobe PC. Carbamazepine increases extracellular serotonin concentration (Lack of antagonism by tetrodotoxin or zero Ca2+). Eur J Pharmacol. 1997;328:153–162
  95. Pratt JA, Jenner P, Johnson AL, Shorvon SD, Reynolds EH. Anticonvulsant drugs alter plasma tryptophan concentrations in epileptic patients (Implications for antiepileptic action and mental function). J Neurol Neurosurg Psychiatry. 1984;47:1131–1133
  96. Biggs CS, Pearce BR, Fowler LJ, Whitton PS. Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine, and their metabolites in the rat brain (An in vivo microdialysis study). J Neurochem. 1992;59:1702–1708
  97. Shukla GS. Combined lithium and valproate treatment and subsequent withdrawal (Serotonergic mechanism of their interaction in discrete brain regions). Prog Neuropsychopharmacol Biol Psychiatry. 1985;9:153–156
  98. Fitton A, Goa KL. Lamotrigine (An update of its pharmacology and therapeutic use in epilepsy). Drugs. 1995;50:691–713
  99. Yoshimura R, Yanagihara N, Terao T, Minami K, Abe K, Izumi F. Inhibition by carbamazepine of various ion channels-mediated catecholamine secretion in cultured bovine adrenal medullary cells. Naunyn Schmiedebergs Arch Pharmacol. 1995;352:297–303
  100. Loscher W, Honack D. Valproate and its major metabolite E-2-en-valproate induce different effects on behaviour and brain monoamine metabolism in rats. Eur J Pharmacol. 1996;299:61–67
  101. Fink K, Medre W, Dooley DMG. Inhibition of neuronal Ca(2+) by gabapentin and susequent reduction of neurotransmitter release from rat neocortical slices. Br J Pharmacol. 2000;130:900–906
  102. Okada M, Hirano T, Mizuno K, et al.  Biphasic effects of carbamazepine on the dopaminergic system in rat striatum and hippocampus. Epilepsy Res. 1997;28:143–153
  103. Zimmer R, Teeklen A, Gundurewa M, Ruther E, Cramer H. Effect of sodium valproate on CSF GABA, cAMP, CGMP and homovanillic acid levels in men. Brain Res Bull. 1980;5(Suppl 2):585–588
  104. Xie X, Hagan RM. Cellular and molecular actions of lamotrigine (Possible mechanisms of efficacy in bipolar disorder). Neuropsychobiology. 1998;38:119–130
  105. Reimann W. Inhibition by GABA, baclofen, and gabapentin of dopamine release from rabbit caudate nucleus (Are there common or different sites of action?). Eur J Pharmacol. 1983;94:341–344
  106. DeLong GR, Teague LA, McSwainKamran M. Effects of fluoxetine treatment in young children with idiopathic autism. [see comments] Dev Med Child Neurol. 1998;40:551–562
  107. Piven J, Gayle J, Chase GA, et al.  A family history study of neuropsychiatric disorders in the adult siblings of autistic individuals. [see comments] J Am Acad Child Adolesc Psychiatry. 1990;29:177–183
  108. Bolton PF, Pickles A, Murphy M, Rutter M. Autism, affective and other psychiatric disorders (Patterns of familial aggregation). Psychol Med. 1998;28:385–395
  109. Gillberg C, Gillberg IC, Steffenburg S. Siblings and parents of children with autism (A controlled population-based study). Dev Med Child Neurol. 1992;34:389–398
  110. Steffenburg S, Gillberg C, Steffenburg U. Psychiatric disorders in children and adolescents with mental retardation and active epilepsy. Arch Neurol. 1996;53:904–912
  111. Minshew N, Luna B, Sweeny J. Oculomotor evidence for neocortical systems but not cerebellar dysfunction in autism. Neuroloy. 1999;52:917–922
  112. Courchesne E, Saitoh O, Yeung-Courchesne R, et al.  Abnormality of cerebellar vermian lobules VI and VII in patients with infantile autism (Identification of hypoplastic and hyperplastic subgroups with MR imaging). Am J Roentgenol. 1994;162:123–130
  113. Courchesne E, Townsend J, Saitoh O. The brain in infantile autism (Posterior fossa structures are abnormal). [see comments] Neurology. 1994;44:214–223
  114. Bachevalier J. Medial temporal lobe structures and autism (A review of clinical and experimental findings). Neuropsychologia. 1994;32:627–648
  115. Cook E. Autism (Review of neurochemical investigation). Synapse. 1990;6:292–308
  116. Chugani DC, Muzik O, Behen M, et al.  Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol. 1999;45:287–295
  117. Statnick MA, Dailey JW, Jobe PC, Browning RA. Abnormalities in brain serotonin concentration, high-affinity uptake, and tryptophan hydroxylase activity in severe-seizure genetically epilepsy-prone rats. Epilepsia. 1996;37:311–321
  118. Favale E, Rubino V, Mainardi P, Lunardi G, Albano C. Anticonvulsant effect of fluoxetine in humans. [see comments] Neurology. 1995;45:1926–1927
  119. Belsito M, Kirk K, Landa R, Law P, Zimmermann A. Lamotrigine therapy for childhood autism (A randomized, double blind, placebo-controlled trial). Neurology. 1998;50:A85
  120. Bowden CL, Calabrese JR, McElroy SL, et al.  A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. [see comments] Arch Gen Psychiatry. 2000;57:481–489

PII: S0887-8994(01)00276-4

Pediatric Neurology
Volume 25, Issue 3 , Pages 199-207 , September 2001

Article Tools